Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer

BJU International

Volumn 101, Issue 3, 2008, Pages 308-312

  Nakabayashi, Mari ^a   Sartor, Oliver ^a   Jacobus, Susanna ^a   Regan, Meredith M ^a   McKearn, David ^a   Ross, Robert W ^a   Kantoff, Philip W ^a   Taplin, Mary Ellen ^a   Oh, William K ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Carboplatin; Chemotherapy; Docetaxel; Hormone refractory prostate cancer

Indexed keywords

ANTIANDROGEN; CARBOPLATIN; DIETHYLSTILBESTROL; DOCETAXEL; EPOTHILONE A; ESTRAMUSTINE; GONADORELIN DERIVATIVE; HYDROCORTISONE; KETOCONAZOLE; NAVELBINE; PACLITAXEL; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; SATRAPLATIN;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; ANDROGENS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; ESTRAMUSTINE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TAXOIDS; TREATMENT OUTCOME;

EID: 37849031527     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.07331.x     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007 57 : 43 66
2. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004 351 : 1513 20
3. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004 351 : 1502 12
4. Kantoff PW, Halabi S, Conaway M et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999 17 : 2506 13
5. Oh WK, Tay MH, Huang J. Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer? Cancer 2006 109 : 477 86
6. Kushner DM, Connor JP, Sanchez F et al. Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial. Gynecol Oncol 2007 105 : 358 64
7. Parmar MK, Ledermann JA, Colombo N et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-22 Trial. Lancet 2003 361 : 2099 106
8. Belani CP, Fossella F. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). Cancer 2005 104 : 2766 74
9. Berry W, Friedland D, Fleagle J et al. A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer. Clin Genitourin Cancer 2006 5 : 131 7
10. Kelly WK, Curley T, Slovin S et al. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 2001 19 : 44 53
11. Oh WK, Hagmann E, Manola J et al. A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer. Clin Cancer Res 2005 11 : 284 9
12. Oh WK, Halabi S, Kelly WK et al. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma. Cancer and Leukemia Group B 99813. Cancer 2003 98 : 2592 8
13. Solit DB, Morris M, Slovin S et al. Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma. Cancer 2003 98 : 1842 8
14. Urakami S, Igawa M, Kikuno N et al. Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer. J Urol 2002 168 : 2444 50
15. Ross RW, Jacobus S, Bubley GJ et al. A phase II study of carboplatin plus docetaxel in men with metastatic hormone refractory prostate cancer who are refractory to docetaxel. 2007 (in press).
16. Oh, WK, Hayes, J, Evan, C et al. Development of an integrated prostate cancer research information system. Clin Genitourin Cancer 2006 5 : 61 6
17. Bubley GJ, Carducci M, Dahut W et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999 17 : 3461 7
18. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000 92 : 205 16
19. Kaplan E, Meirer P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958 53 : 457 81
20. Oh WK, Jacobus S, Ross RW, et al. A phase II trial of docetaxel plus carboplatin in hormone refractory prostate cacner (HRPC) in patients who have progressed after prior docetaxel chemotherapy. 2007 Prostate Cancer Symposium 2007: Abstract 238
21. Sternberg CN, Petrylak D, Witjes F et al. Satraplatin (S) demonstrates significant clinical benefits for the treatment pf patients with HRPC. Results of a randomized phase III trial. ASCO Annu Meeting Proc 2007 25 (18S Abstract 5019
22. Petrylak DP, Sartor O, Witjes F et al. A phase III, randomized, double-blind trial of satraplatin and prednisone vs placebo and prednisone for patients with hormone refractory prostate cancer (HRPC). ASCO Annu Meeting Proc 2007 25 (18S Abstract 145
23. Johnson SW, Stevenson JP, O'Dwyer VT. Cisplatin and its analogues. In DeVita VT, Hellman S, Rosenberg SA, Cancer: Principles and Practice of Oncology. Philadelphia : Lippincott, Williams & Wilkins, 2001 : 376 88
24. Nguyen HN, Sevin BU, Averette HE et al. Cell cycle perturbations of platinum derivatives on two ovarian cancer cell lines. Cancer Invest 1993 11 : 264 75
25. Ormerod MG, Orr RM, Peacock JH. The role of apoptosis in cell killing by cisplatin: a flow cytometric study. Br J Cancer 1994 69 : 93 100
26. Salles B, Butour JL, Lesca C, Macquet JP. cis-Pt(NH3) 2Cl2 and trans-Pt(NH3) 2Cl2 inhibit DNA synthesis in cultured L1210 leukemia cells. Biochem Biophys Res Commun 1983 112 : 555 63